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CHAPTER I 
INTRODUCTION 
Coronary heart disease (CHD) is a major public health 
problem in the United States. Despite substantial success 
in reducing premature deaths from CHD in the past two 
decades, this disease continues to kill more than 500,000 
Americans annually and is still our nation's leading cause 
of death and disability. About one million Americans suffer 
myocardial infarctions each year, and more than six million 
have symptoms of CHD (43). In addition, significant degrees 
of asymptomatic CHD are very common in our population. The 
impact of the illness on the economy has been estimated to 
be over $50 billion annually for care and lost earnings and 
productivity related to CHD (42). 
CHD is the result of atherosclerosis, in which deposits 
of cholesterol and other lipids, together with cellular 
reactions, thicken artery walls. This process gradually 
reduces the lumen of the artery and restrict:s blood flow. 
Inadequate blood flow can cause injury to or death of tissue 
beyond the site of reduced flow. on the coronary arteries, 
this leads to myocardial infarction or sudden death. Many 
factors influence not only whether a person will develop CHD 
but also how rapidly atherosclerosis progresses. Genetic 
predisposition, gender, and advancing age are recognized as 
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major risk factors for CHD that cannot be modified. High 
blood cholesterol, cigarette smoking, and high blood 
pressure are considered the primary risk factors for CHD 
which can be modified through lifestyle changes (42). 
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Cholesterol is a fat-like substance (lipid) that is a 
key component of cell membranes and a precursor of bile 
acids and steroid hormones. Typical of lipids, cholesterol 
and triglycerides are not water soluble. In order to be 
solubilized in the blood and transported through the body 
the cholesterol and triglycerides are bonded to protein 
macromolecules. The combinations are called lipoproteins. 
There are three major examples in the blood, namely HDL-C or 
high density lipoprotein cholesterol, LDL-C or low density 
lipoprotein cholesterol, and VLDL-C or very low density 
lipoprotein cholesterol. Total serum cholesterol found in 
the normal fasting individual is distributed as follows: 
HDL-C 20 to 30%, LDL-C 60 to 70%, and VLDL-C, which are 
largely composed of triglyceride, 10 to 15% (41). The serum 
cholesterol level is determined partly by inheritance and 
partly by the fat and cholesterol content of the diet. 
Other factors such as obesity and physical inactivity can 
also play a significant role (41). 
The role of the HDL-C component is to act as a type of 
shuttle as it takes up cholesterol from the blood and body 
cells and transfers it to the l1ver, where it is used to 
form bile acids. The bile acids are involved in the 
digestion process, with some of them passing out with the 
stool, thus providing the body with a major route for 
excretion of cholesterol (45). 
LDL-C, on the other hand, transports cholesterol from 
the liver to various body cells, where it is deposited for 
cell functions. LDL-C is very high in cholesterol, so when 
LDL-C levels are excessively high, it contributes to the 
buildup of atherosclerosis (45). 
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Because the risk of CHD appears to be directly 
proportional to the blood levels of total cholesterol and 
LDL-C and inversely proportional to the level of HDL-C, 
efforts to measure the levels of the individual blood lipids 
have become extremely important in recent years (15). 
Common clinical uses of cholesterol measurement include 
advising patients with regard to their risk of developing 
CHD based on their lipoprotein profile; monitoring a 
therapeutic response to exercise, weight loss, or 
pharmacologic intervention; and serving as a psychological 
reinforcement following CHD risk factor modification. An 
accurate and reproducible method of cholesterol 
determination is required for all three applications (51). 
A concerted national effort to identify and treat every 
American adult at high risk for CHD due to high blood 
cholesterol levels is expected to contribute to lower CHD 
morbidity and mortality rates. According to the National 
Cholesterol Education Panel (NCEP), all adults should know 
their blood cholesterol level, be aware of the implications 
of elevated cholesterol, and seek the help of a physician 
should treatment be necessary (28). 
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The results of the Coronary Primary Prevention Trial, 
the Coronary Angiography Lipid Lowering Trial of the 
National Heart, Lung, and Blood Institute (NHLBI), and other 
plasma lipid-altering trials have focused attention on the 
central role of lipoproteins and cholesterol in the 
atherosclerotic process. A review of studies using 
arteriography to assess the extent of stenosis highlights 
the important atherogenic role of LDL-C and the 
antiatherogenic role of HDL-C (51). The NCEP concludes that 
LDL-C figures offer more precise information than total 
cholesterol as a risk factor, and is therefore preferred for 
clinical decisions about interventions to lower blood 
cholesterol, especially in patients who may be candidates 
for cholesterol-lowering drugs (41). The Adult Treatment 
Panel of the NCEP has predicted that the LDL-C value will be 
the key determinant upon which a clinical decision will be 
based to intervene with cholesterol-lowering therapy (28). 
The basis for the experimental determination of 
cholesterol and its fractions in any body fluid, e.g. serum, 
plasma, or cerebrospinal fluid, is the intensity of a color 
that occurs in the product(s) of a chemical reaction. At 
the present time, no clinical laboratories are able to 
measure the LDL-C fraction directly because no reaction has 
been found where the color produced is exclusive to LDL-C. 
Instead it is calculated based on measurements of total 
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cholesterol {TC), HDL-C, and triglycerides {TG) {45). Based 
on considerable evidence the VLDL-C fraction is taken to be 
equal to one-fifth of the TG value in which case the LDL-C 
concentration, the only unknown, can be estimated using the 
Friedewald formula {17): 
LDL-C = TC - {HDL-C + TG/5) 
Concentrations are usually expressed in the units milligrams 
per deciliter (45), although molarity (molesfL) is becoming 
more prevalent. 
In practice, TC is measured first. Subsequently HDL-C 
is measured in a second test after the other lipoproteins 
have been removed from the sample. The removal is generally 
accomplished by selective precipitation with one of the 
commonly used reagents, such as manganese heparin, dextran 
sulfate, or magnesium phosphotungstate {51). There are no 
known precipitating reagents that will selectively remove 
HDL-C and VLDL-C and allow one to measure LDL-C directly. 
TG is measured in a third unrelated test. 
If one accepts the NCEP conclusion that LDL-C is a 
better predictor of CHD, then there is a need for a method 
that will accurately and precisely determine LDL-C 
cholesterol levels to assess a person's risk for CHD and to 
monitor treatment {44). 
This investigation is intended to compare the results 
from a new method in which LDL-C is measured directly with 
the well-accepted method of calculating LDL-C levels just 
described. The new method, referred to as the Chugaev 
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reaction,, and the current, well-accepted method, referred to 
as the Allain-Trinder method, are described more fully in 
Chapter III. If the results of the investigation support 
the hypothesis that the direct measurement of LDL-C is 
superior to the calculation of LDL-C, it will provide a 
means for accurately assessing risk for CHD, and/or 
monitoring treatment for hyperlipidemia. 
Statement of the Problem 
The Allain-Trinder method does not measure serum levels 
of LDL-bound cholesterol, but rather calculates it based on 
measurements of total cholesterol, HDL-C, and triglycerides. 
The Chugaev reaction, in which the LDL-C levels are measured 
directly will be tested, and the results from both methods , 
will be compared. 
Hypothesis 
There will be no significant difference in the LDL-C 
values obtained by the Chugaev method of direct measurement 
of serum and the Allain-Trinder method of calculating LDL-C. 
Limitations of the Study 
In order to measure LDL-C directly, a new color 
reaction is required. The limitations to the new process 
are: no attempts will be made to separate the fractions; the 
intensity and stability of the color are dependent on the 
experimental conditions; the range of cholesterol levels 
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that can be measured is uncertain. The most serious 
limitation to the study is the magnitude of the experimental 
errors associated with both methods. 
Delimitations of the Study 
1. Subjects will be volunteers who request a lipid 
profile/analysis from the Oklahoma State University Wellness 
center. No attempt will be made to select only those 
volunteers at high risk for CHD. 
2. Only one trial from both methods will be made for 
each sample. 
Assumptions 
1. The subjects will have fasted for at least 12 hours 
prior to blood samples being taken. 
2. The Allain-Trinder method of determining 
cholesterol and its fractions is standardized according to 
the College of American Pathologists (CAP). 
3. Reagents for the Chugaev method remain stable over 
time. 
4. The reference materials are pure. 
5. The new color reaction has no interferences from 
other const1tuents in the serum. 
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Definition of Terms 
Conceptual 
Angina pectoris. Pain in the chest and arms or jaw due 
to a lack of oxygen to the heart muscle, usually when the 
demand for oxygen is increased during exercise and at times 
of stress (3). 
Angiography. A procedure that enables blood vessels to 
be seen on film after the vessels have been filled with a 
contrast medium (a substance that is opaque to X rays) (3). 
Arteriography. Another name for angiography (3). 
Arteriosclerosis. A group of disorders that causes 
thickening and loss of elasticity of artery walls. 
Atherosclerosis is the most common type (3). Commonly 
called hardening of the arteries (45). 
Atherosclerosis. A very common form of 
arteriosclerosis, in which the arteries are narrowed by 
deposits of cholesterol and other material in the inner 
walls of the artery (45). It is the type of arteriosclerosis 
most influenced by lifestyle factors (62). 
Cardiovascular Disease (CVD). All diseases affecting 
the cardiovascular system including coronary heart disease, 
atherosclerosis, high blood pressure, stroke, rheumatic 
fever, and rheumatic heart disease (53). Atherosclerosis is 
the most prevalent form of CVD (62). 
Cholesterol. A steroid alcohol found in animal fats. 
This pearly, fatlike substance is implicated in the 
narrowing of the arteries in atherosclerosis (45). 
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Chylomicrons. The lipoprotein formed in the intestinal 
wall cells following digesting and absorption of fat (62). 
They serve primarily to transport exogenous triglycerides to 
tissue sites for storage and utilization (37). 
Coronary heart disease (CHD). Atherosclerosis in the 
arteries feeding the heart muscle (62). 
High density lipoprotein cholesterol (HDL-C). 
Cholesterol is carried by the high density lipoprotein to 
the liver. The liver then uses the cholesterol to form bile 
acids which are finally excreted in the stool (45). 
Lipids. A general term used for several different 
compounds which include both solid fats and liquid oils. 
There are three major classes of lipids: triglycerides (the 
principal form of fat in body fat), phospholipids (important 
constituents of cell membranes), and sterols such as 
cholesterol (45). 
Lipoprotein. The carrier protein for lipids (53). 
There are four types of lipoproteins: chylomicrons, low 
density lipoprotein (LDL), very low density lipoprotein 
(VLDL), and high density lipoprotein {HDL) (45). 
Low density lipoprotein cholesterol (LDL-C). 
Transports cholesterol from the liver to other body cells. 
LDL-C is often referred to as "bad" cholesterol because it 
may be taken up by muscle cells in arteries and it has been 
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implicated in the development of atherosclerosis (45). This 
type of lipoprotein is derived from VLDL-C as cells remove 
triglycerides from them (62). 
Myocardial infarction. A common form of heart attack, 
in which the blockage of a coronary artery causes the death 
of a part of the heart muscle (45). 
Very low density lipoprotein cholesterol (VLDL-C). 
Transports triglycerides to body tissues (45). This type of 
lipoprotein is made by liver cells and, to some extent, by 
intestinal cells (62). 
Functional 
Fasting. A state in which a subject of the study had 
taken in nothing by mouth (except water) for at least 12 
hours prior to a blood sample being taken. 
Reference Materials. Lipoprotein fractions that were 
(a) separated by ultrafiltration and commercially available 
from Sigma Chemical Company and (b) separated by 
ultracentrifugation and made available by the lipoprotein 
laboratory of the Oklahoma Medical Research Foundation. 
Description of Instruments 
Centrifuge. A high-speed clinical micro-centrifuge 
manufactured by Allied Fisher Scientific, Model No. 56A 
operated at a speed of 11,500 revolutions per minute. 
Incubator. A water-bath with close temperature 
control, manufactured by Precision, Model 181, and operated 
at an incubation temperature of 67° Centigrade. 
Pipettes. Automatic, adjustable micro-pipettes 
manufactured by Rainin Instruments Co., Inc., capable of 
delivering sample aliquots from 10 to 1000 microliters. 
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Spectrophotometer. This instrument, a Hitachi 100-SOA, 
measures the intensity of light transmitted or absorbed by a 
specimen as a function of wavelength of the incident light. 
CHAPTER II 
A SELECTED REVIEW OF LITERATURE 
The text of Chapter I was a description of the CHD risk 
factors based upon measured values of total serum 
cholesterol andjor the individual lipoprotein fractions. In 
this chapter the history behind the measurements and how the 
conclusions were reached are described. 
Review of Recent Studies 
That a relationship exists between elevated blood 
cholesterol and CHD has been known for nearly a century {50) 
and its origin has been the focus of laboratory 
investigations for over 50 years {23). With the added 
ability over the last 30 years, and especially the last 15 
years, to separate and investigate the various lipids and 
lipoproteins in greater detail, a wider array of potential 
parameters needs to be considered in reviewing the causes of 
the atherosclerotic process {50). 
One of the most productive of all epidemiologic 
investigations was the Framingham Heart Study {FHS). The 
results from this study have played a major role in 
explaining the nature of CHD risk factors and their relative 
importance {52). Other major study programs in North 
12 
13 
America which include the Lipid Research Clinics Prevalance 
Mortality Follow-up Study (LRCF), the Lipid Research Clinics 
Coronary Primary Prevention Trial (LRC-CPPT), and the 
Multiple Risk Factor Intervention Trial (MRFIT) have made 
important contributions to our understanding of these risk 
factors (3). These studies produced an abundance of 
epidemiologic information that seem to confirm that specific 
factors are directly associated with an increased risk for 
the development of CHD (52). 
The FHS was a prospective epidemiological study of 
cardiovascular disease (CVD). Beginning in 1949 a group of 
5,209 men and women, then aged 30 to 59 years, were enlisted 
into a longitudinal study (21). Since then, the progress 
of each volunteer has been followed by means of routine 
biennial medical examinations where possible, and 
and from morbidity and mortality data provided by hospitals 
and other sources. The measurements of fasting HDL-C and 
triglyceride levels were introduced in 1969 (21,8). 
In a report of the FHS written by Gordon et al. (21) 
and based upon four years of surveillance, the major potent 
lipid risk factor for CHD was thought to be HDL-C, which 
showed an inverse relationship with the incidence of CHD (p 
< 0.001) in both men and women. An association with the 
incidence of CHD (p < 0.05), but one of much less importance 
was observed for LDL-C. That correlation was direct, i.e., 
not inverse. 
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Again, based on the FHS data, Lavie et al. {29) 
reported that CHD is most prevalent when LDL-C is high and 
HDL-C is low; it is very rare when LDL-C is low and HDL-C is 
high. High and low in this sense are undefined relative 
numbers. It was also explained, however, that even when 
LDL-C levels are very high, CHD is fairly uncommon if HDL-C 
levels are 65 mgfdL or more, and it is rare when HDL-C 
levels are as high as 85 mg/dL. And, on the other hand, 
even when LDL-C is very low {100 mg/dL), CHD is still common 
when HDL-C levels are also very low (25 mg/dL). 
Using data from the Framingham investigation, Castelli 
et al. developed a relative risk score that was based on the 
ratio of total cholesterol to HDL-C {TC/HDL-C) {51). This 
risk ratio is still commonly used in clinical practice (51). 
A suggestion was made that the ratio of TC to HDL-C is the 
best predictor of developing CHD (15). To be considered at 
low risk, this ratio, TC/HDL-C, should be less than 5.0 in 
males and less than 4.5 in females. The problem with any 
ratio, however, is that it gives no indication by itself of 
the absolute values. Do ratios of 5 that are equal to 
350:70 and 200:40 signify equivalent risk factors? It was 
proposed, therefore, that if the TC/HDL-C ratio is used for 
r1sk assessment, then absolute values must also be indicated 
( 15) 0 
The Lipid Research Clinics Prevalence Study was also an 
epidemiological study of lipid and other cardiovascular risk 
factors and was done during 1972-1976 in 10 collaborating 
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North American Centers (19). Fasting plasma lipid levels 
and selected medical and sociodemographic data were obtained 
for more than 70,000 men and women. The selected 
populations were deliberately diverse, covering a broad 
range of geographic, socioeconomic, occupational, age, sex, 
and ethnic groups. In 1977, a mortality follow-up study 
(LRCF) was begun involving all participants in the 
Prevalence study who were at least 30 years old at that time 
(23). The primary objective of this study was to acquire 
data on the prevalence of difference types of 
hyperlipoproteinemia in various age and ethnic groups (33). 
The LRC-CPPT study was a multicenter, randomized, 
double-blind trial of the efficacy of lowering LDL-C levels 
in reducing CHD risk in 3,806 asymptomatic middle-aged men 
with primary hypercholesterolemia {plasma cholesterol ~ 265 
mgfdL {31,32). 
Part I of the LRC-CPPT (31) was designed to test the 
hypothesis that lowering total cholesterol and LDL-C by diet 
or drugs or both ~ill reduce the subsequent incidence of 
CHD. In part II of the LRC-CPPT (32) the quantitative 
impact of cholesterol lowering on CHD incidence was 
evaluated. The combined LRC-CPPT findings confirmed that 
reducing total cholesterol by lowering LDL-C levels can 
diminish the incidence of CHD morbidity and mortality in men 
whose high risk for CHD is a consequence of elevated LDL-C 
levels. A decrement of 22.3 mgfdL in LDL-C levels was 
associated with a 16% to 19% reduction in CHD risk. 
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The MRFIT study was a randomized multicenter clinical 
trial to test the effect of a multifactor intervention 
program on mortality from CHD in 12,866 high-risk men aged 
35 to 57 years. The subjects were without clinical CHD 
manifestations but were at high CHD risk (upper 10-15%) 
because of a combination of hypertension, cigarette smoking, 
and elevated plasma cholesterol (40). 
An analysis of the MRFIT data by Stamler et al.(48) 
demonstrated that the relationship between serum cholesterol 
and CHD is not a threshold one, but a continuously graded 
one that is a dominant factor in assessing risk for the 
great majority of middle-aged American men. In other words, 
the conclusion is that the great majority of adults in the 
United States are at increased CHD risk because of their 
status in regard to this factor, and not only those relative 
few in the highest or the two highest quintiles of the 
distribution. Specifically, serum choleterol levels of 
about 180 mgfdL and above are associated with increased risk 
for middle-aged American men, and not just levels that are 
equal to or greater than 220 to 240 mgjdL. 
In 1989, Gordon et al. (19) analyzed pooled data from 
these four large prospective epidemiologic studies (FHS, 
LRCF, LRC-CPPT, and MRFIT), and a conclusion was reached 
that for every 1 mg/dL rise in HDL-C, the CHD risk dropped 
about 2% in men and 3% in women, and cardiovascular 
mortality decreased by 4% in men and 5% in women. 
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Lavie et al. (29) seemed to agree with Gordon and 
others that HDL-C is the most important lipid risk factor in 
assessing the risk for CHD, even more important than TC or 
LDL-C. A strong case is presented for emphasizing the 
measurement of HDL-C in adults and for treating most 
patients with low HDL-C levels. 
Establishment of the National 
Cholesterol Education Program 
A large body of evidence of many kinds has linked 
elevated blood cholesterol levels to CHD (10). However, 
many doubts still remain about the weight of the evidence 
for a cause and effect relationship. To resolve some of 
these questions, the National Heart, Lung, and Blood 
Institute (NHLBI) and the National Institutes of Health 
(NIH) Off'ice of Medical Applications of Research convened a 
Consensus Development Conference on Lowering Blood 
Cholesterol to Prevent Heart Disease'in 1984. 
Based upon a series of expert presentations and reviews 
of all of the available data, a consensus panel reached the 
following conclusions: the elevation of blood cholesterol 
levels is a major cause of coronary artery disease; and it 
has been established beyond a reasonable doubt that lowering 
elevated blood cholesterol levels (specifically, blood 
levels of LDL-C) will reduce the risk of heart attacks 
caused by CHD (10). 
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Among the recommendations arising from this conference 
were: individuals with high-risk cholesterol levels must be 
identified and treated; changes in eating patterns for 
members of the general public must be developed and 
encouraged; and a national cholesterol educational program 
must be created and implemented. In response to this the 
National Cholesterol Education Program (NCEP), which the 
NHBLI had begun to plan in early 1984 was launched in 
November 1985 (42). The goal of the NCEP was to reduce the 
prevalence of elevated blood cholesterol in the United 
States, and thereby contribute to the reduction of CHD 
morbidity and mortality. 
Since its inception the NCEP has issued periodic 
reports developed by its Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel or ATP) and its Laboratory 
Standardization Panel (LSP) on the validity of measurements 
(42). In addition, the Population Panel issued a report 
based on an intensive review of the scientific bases for 
making blood cholesterol-lowering recommendations and 
particularly eating pattern recommendations that are offered 
to the general public. A fourth panel will report later on 
blood cholesterol in children and adolescents (42). 
In 1987, the NCEP Adult Treatment Panel recommended 
that all u.s. citizens older than 20 years have their 
cholesterol level tested. A desirable total cholesterol 
level was defined to be below 200 mgfdL, borderline-high is 
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in the range 200-239 mgjdL, and high risk at levels above 
240 mgjdL. Similarly a desirable LDL-C value was defined to 
be below 130 mgjdL, borderline-high from 130 to 159 mgjdL, 
and high risk at levels above 160 mgjdL. For patients with 
multiple risk factors, including history of CHD or two other 
known risk factors, intervention at even lower levels of 
cholesterol was recommended (41). 
In summary, the Adult Treatment Panel report has given 
priority to the treatment of elevated LDL-C concentratons 
but has not ignored the importance of low HDL-C levels. The 
report designated low HDL-C level as a major risk factor for 
CHD and recommended that HDL-C be measured for any patient 
deemed to be at high risk for CHD. The rationale for focus 
on elevated LDL-C concentrations is based on strong 
scientific evidence (25). Data that indicate increased 
levels of LDL-C is a major atherogenic factor are derived 
from several types of epidemiologic studies, from clinical 
evidence in patients with familial hypercholesterolemia, 
from investigations in experimental animals, from analysis 
of pathologic specimens, and from recent studies in tissue 
culture (25) . 
The panel also determined that therapeutic reduction of 
high LDL-C concentrations will decrease the risk for CHD. 
Clinical trials have shown that lowering serum LDL-C levels 
by diet or drugs will reduce the incidence of CHD. Because 
of this combined evidence for causation and therapeutic 
benefit, the Adult Treatment Panel concluded that the major 
emphasis on therapy for cholesterol as a risk factor should 
be directed toward patients with high levels of LDL-C {25). 
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The NCEP's emphasis on the importance of LDL-C as a 
risk factor for CHD as opposed to the TC/HDL-C ratio 
established by the Framingham investigation is based on the 
following rationale. Several opinions have been expressed 
about the validity of HDL-C data in relation to CHD, many of 
which are nonsupportive. 
If HDL-C is to become part of a standard risk profile 
for CHD, great care must be given to the precision in the 
laboratory measurements. A good laboratory can achieve a 
technical error of 5 mgfdL in measuring this lipid. But 
when it is remembered that an average HDL-C level for adult 
men is around 45 mgfdL and a significantly high risk of CHD 
is evident at 35 mgfdL, it is clear that a technical error 
of 5 mgfdL is by no means a comfortable one {21). 
In addition, since HDL-C is subtracted in determining 
LDL-C, the errors are reciprocal, substantially compromising 
the overall estimation of CHD risk because the risk 
relationships are also opposite (56). 
The accurate determination of HDL-C values requires 
constant attention to detail and adequate quality control. 
Even in a proficient laboratory, the absolute limit of 
reproducibility of HDL-C measurements may limit the way 
patient's values can be clinically used {51). 
Grundy, et al. {25) cite the following reasons for not 
recommending universal screening for low levels of HDL-C: 
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(1) In the absence of CHD or other risk factors, the 
risk for CHD is not increased markedly in those who have TC 
levels in the range of 200-239 mgjdL, compared with the risk 
at levels below 200 mg/dL. 
(2) Laboratory costs associated with generalized 
testing would increase. All persons tested would require at 
least two tests (TC and HDL-C) and probably three tests (TC, 
HDL-C, and TG, with calculation of LDL-C). Interpretation 
and discussion by the physician would also increase costs. 
(3) The methods for estimating HDL-C have not been well 
standardized. Some current methods systematically 
underestimate true HDL-C levels which will result in an 
excessive number of individuals being classified as having 
low HDL-C levels. An uncertainty of a few milligrams per 
deciliter in HDL-C has little effect on the clinical 
interpretation of the estimated LDL-C level, but a 
relatively small error can have an important affect on the 
interpretation of the clinical significance of the HDL-C 
levels. 
Warnick (56) adds that accuracy in the HDL-C 
measurement is of particular importance since HDL-C is a 
powerful inverse predictor of CHD risk which is expressed 
over a narrow concentration range. The NCEP recommended 
cutpoint of 35 mgfdL differs only little from the usual 
population mean of approximately 50 mgfdL. 
Superko et al. (51) investigated the difficulties 
inherent in determining HDL-C values, and concluded that 
often HDL-C measurements lack sufficient accuracy to be of 
practical use in an individual clinical setting. 
Frolich et al. (18) report that the current problems 
with the accuracy and precision of the serum HDL-C assay 
prevent it from being the single most important test for 
assessment of the lipid risk factors for CHD. 
Laboratory Standardization Panel 
Recommendations 
In 1988 the Laboratory Standardization Panel (LSP) of 
the NCEP defined and established goals for precision and 
accuracy of TC, TG, and HDL-C measurements to minimize the 
effect of laboratory error (28). Accuracy refers to the 
"closeness to the true value" while precision reflects the 
test-to-test and day-to-day reproducibility (18). Without 
these defined goals and suitable reference standards, 
accurate classification of risk is meaningless (7) . 
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The LSP recommends that, as a national goal, clinical 
laboratories should initially achieve an overall precision 
consistent with a coefficient of variation (CV) of ±5% or 
less; ultimately, laboratories should achieve a CV of ±3% or 
less. CV is defined to be a relative measure of precision 
and is equal to the standard deviation of a set of values 
divided by the mean, which when multiplied by 100 can be 
expressed as a percentage (28). 
The LSP recommends that biases (departures from the 
true value) in methods presently in use should not exceed 
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±5% and that ultimately a national goal of ~ 3% bias should 
be achieved (28). By this definition, bias is a 
quantitative measure of the degree of inaccuracy. The 
difference between the true, accepted, or expected value and 
the observed value, is expressed either in the units of the 
measurement or as a percentage. 
Accuracy and precision are of vital importance in 
assessing serum cholesterol levels (18). Unfortunately, 
accuracies are very low and imprecisions of measurements are 
very high. Even the measurement of total serum cholesterol 
is fraught with problems and it is now apparent that the 
goal of ±3% inaccuracy and precision may lead to 
misclassification of large numbers of patients (18). 
Consider the sliding scale for CHD that is based upon those 
levels: < 200 mgfdL, 200-239 mgfdL, and ~240 mgfdL. The 
middle range is only 40 mgfdL wide and in order to get a 95% 
confidence level in the risk assignment, the accuracy and 
the bias must both be <±3% (61). 
Future Goals in Measurement 
LDL-C has been recommended by the NCEP Adult Treatment 
Panel as the determining factor in initiating dietary and 
drug treatment (14). Considering its importance, the 
methodology for the measurement of LDL-C is substantially 
lacking. The only convenient routine is to calculate it 
from known values for total cholesterol, HDL-C, and VLDL-C 
levels as the remainder in the Friedewald formula (56). 
Laboratory performance specifications have not been 
established for LDL-C cholesterol {56). 
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Methods for quantitation of the lipoprotein risk 
factors are steadily improving, but work still remains to be 
done to achieve acceptable routine performances by 
diagnostic laboratories. Ultracentrifugation, the only 
known method. available for the direct separation of LDL-C, 
is tedious, expensive and requires a'large specimen volume 
{34, 56, 57, 60); validation of a simpler whole serum method 
with equivalent results would be desirable {56). 
Based on the importance of LDL-C in risk classification 
and treatment, better methods for quantification of LDL-C 
cholesterol, especially direct methods, are needed {56). 
Summary 
The positive association of LDL-C and total serum 
cholesterol and the negative association of HDL-C with CHD 
risk are well established. From the literature reviewed in 
this chapter, it is evident that there is considerable 
difference of opinion as to which of these factors is the 
strongest predictor of coronary heart disease. The pooled 
data from the four major studies reviewed {Framingham Heart 
Study, Lipid Research Clinics Prevalance Mortality Follow-up 
Study, Lipid Research Clinics Coronary Primary Prevention 
Trial, and the Multiple Risk Factor Intervention Trial) 
showed a powerful inverse relationship between HDL-C and the 
likelihood of developing CHD. However, as pointed out, the 
difficulties inherent in determining HDL-C values limit its 
value as an important lipid risk factor in assessing the 
risk for CHD. 
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The National Cholesterol Education Program acknowledged 
the importance of HDL-C levels of less than 35 mgfdL as a 
coronary risk fact,or, but stated that LDL-C offers more 
precision as a risk factor and is therefore preferred for 
clinical decisions about interventions to lower blood 
cholesterol. Accepting the recommendations of the NCEP that 
LDL-C is the better predictor of CHD, it was determined to 
be the focus of this study. 
CHAPTER III 
METHODS AND PROCEDURES 
This study compared the results from a method developed 
to directly measure the LDL-C fraction of serum cholesterol 
with the results from a well-accepted method of calculating 
LDL-C levels. The methods and procedures for collecting 
samples and preserving patient anonymity were approved by 
the Oklahoma State University Institutional Review Board. 
Analytical Detection of Cholesterol 
Cholesterol levels cannot be measured without first 
reacting the molecule to form a colored derivative whose 
intensity can be measured and is known to be proportional to 
the amount of cholesterol present. The well-accepted 
method, also the only convenient method, was developed by 
Allain in 1974 (2) and uses a color derivatization reaction 
described by Trinder in 1969 (55). In all subsequent 
discussions the reaction will be referred to as the Allain-
Trinder method. 
The contribution from Allain was the two-step double 
enzymatic reaction using a single reagent system (2) in 
which cholesterol is derivatized to cholest-4-en-3-one 
according to: 
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Cholesterol 
Cholesterol Esters + H2o -----------> 
Esterase 
Cholesterol 
Cholesterol + Fatty 
Acids 
Cholesterol + o 2 -----------> Cholest-4-en-3-one + H2o 2 
oxidase 
The hydrogen peroxide produced in the Allain reaction 
becomes a reagent in the Trinder reaction. The product of 
interest is the red-colored quinoneimine dye. 
2H2o 2 + 4-Aminoantipyrine + p-Hydroxybenzenesulfonate 
Peroxidase 
-----------> Quinoneimine Dye + 4H2o 
This is the current, "state-of-the-art" method for 
cholesterol measurement. This is also the procedure to 
which all of the imprecision problems previously described 
are related. 
The quinoneimine dye has a visible absorbance maximum 
at 500 nm. The intensity of the color produced is directly 
proportional to the total cholesterol concentration in the 
sample because of the one-to-one relationship in the second 
equation between cholesterol and H2o 2 • 
This reaction is done at 37° c, which is normal body 
temperature and the temperature at which the enzymes 
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function. Temperature and incubation time for the reactions 
were chosen that produce the most color intensity and color 
stability in the quinoneimine dye. 
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Of the three lipoprotein cholesterol fractions only the 
HDL-C can be measured directly. The low density fractions 
are selectively removed from the total serum by adding a 
precipitating agent. Those commonly used and approved by 
the various regulatory agencies are manganese heparin (57), 
magnesium phosphotungstate (4}, and dextran sulfate (58). 
Heparin-manganese is the precipitating agent recommended by 
the NCEP and Centers for Disease Control (CDC). Because it 
involves a protracted and complex procedure, it is used 
primarily in regulatory laboratories and it is not used for 
broad screening programs. Magnesium phosphotungstate is the 
most common precipitating agent used, but it is sensitive to 
separation conditions. Dextran sulfate is much more 
convenient to use in routine screening, and it is the 
precipitating agent used by Roche Biomedical Laboratories. 
This agency is the source laboratory for Allain-Trinder data 
in this work. There are numerous possible sources of error 
in the measurement of the fractions with the enzymatic 
method, including the following: 
1. Cholesterol is not measured directly; rather, it is 
assumed that the number of H2o2 molecules produced by the 
reaction is equal to the number of cholesterol molecules 
entering the reaction. It is the H202 that reacts with the 
chromogen and produces the color, not the cholesterol. H2o2 
is known to be an unstable compound and is not a selective 
redox agent. 
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2. Serum is not homogeneous, which may result in sample 
inconsistencies. In other words, it could oxidize other 
compounds that might be present in random serum samples. 
3. Only one measurement was performed on each sample. 
4. Precipitation of LDL-C and VLDL-C may not be 
complete or totally selective. 
5. The estimation of VLDL-C as being TG/5 is not 
always accurate, particularly when triglycerides are in 
excess of 400 mgfdL. 
Measurement of total cholesterol is also subject to 
error due to the following: 
1. The same problem involving H2o2 described above. 
2. Blood cells may be lysed during the reaction, which 
produces a red color in the serum that can interfere with 
the absorption measurement at 500 nm. 
The proposed method, referred to as the Chugaev 
reaction, is an attempt to reduce these errors in 
measurement. The method was first described in the chemical 
literature in 1910 (9). The reagent is a 2:1 mixture of 27% 
ZnC12 in glacial acetic acid and 98% acetyl chloride. The 
reaction is done at elevated temperatures and the color is 
produced by the cholesterol molecule directly. The method 
is non-enzymatic and distinction among the fractions is 
based upon the selectivity of the reagent for cholesterol in 
different lipid environments. 
The intensity of the color produced by the reaction is 
measured using absorption spectrophotometry. A source of 
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white light is directed through a prism which separates the 
light into the colors of the spectrum ranging from red (750 
nm) to violet (360 nm). Individual wavelengths are selected 
by rotating the prism. The beam is led through a slit 
opening and illuminates a cuvet which contains the serum 
sample. The result is a representation of the absorption 
spectrum on paper with absorbance on the y axis as a 
function of the wavelength in nanometers on the x axis. 
Generally speaking, the linear relationship that exists 
between the color intensity (absorption) and the quantity of 
material is determined through the use of standard 
references in which the exact amounts of the materials are 
known. Concentrations of cholesterol were calculated from 
the absorbance measurements made at selected wavelengths. 
Hazards of the Method 
Standard precautions for handling human blood samples 
were observed during the experiment. Since both acetyl 
chloride and ZnC12 are corrosive and toxic substances, 
additional precautions were taken: sealed containers were 
used at all times, and all work was done under a fume hood. 
The blood samples and reagents were disposed of according to 
Occupational Safety and Health Administration (OSHA) 
regulations. 
Testing Procedures 
The subjects were volunteers who requested a lipid 
profile from the Oklahoma State University in September, 
October, and November, 1991. No attempt was made to select 
subjects according to demographic classification, and no 
demographic data was collected. They were instructed to 
report to the Wellness Center laboratory having fasted for 
at least 12 hours previous to their arrival. Written 
informed consent, as shown in Appendix A, was obtained from 
each subject in accordance' with institutional guidelines. 
Clinical Laboratory Procedures 
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A venous blood sample was drawn from the brachial fossa 
of either the right or left arm of each subject. A standard 
aseptic venipuncture technique was employed with the 
tourniquet being released prior to removal of the #21 gauge 
needle. All subjects were in the sitting position during 
venipuncture. Vacutainertm red stoppered tubes (serum 
separation tubes, SST) were used in venous collection. 
These have a floating gel to aid in separation of the red 
cells from the serum. One tube, approximately 10 mL, per 
subject was collected. 
All venous samples were allowed to stand at room 
temperature for a minimum of 30 minutes and a maximum of 1 
hour 30 minutes until a clot formed in the tube. The 
samples were then centrifuged at a speed of 5,000 
revolutions per minute for ten minutes in a table top 
clinical centrifuge (Roche Biomedical Laboratories VanGuard 
6000). The gel separated the red cells from the serum. 
32 
A 1 mL aliquot of the serum was aspirated using a 
variable volume Rainin Pipetmantm and transferred into a new 
10 mL glass vial with screw cap. This portion of the sample 
was taken to the Oklahoma State University Department of 
Chemistry, Room B002 Physical Sciences Building I, for 
measurement by the Chugaev method. The Vacutainertm tubes 
were collected by Roche Biomedical Laboratories personnel 
for measurement according to the Allain-Trinder method 
described above, at its Kansas City, Missouri, regional 
laboratory. 
The Chugaev reaction was performed on 10 microL of 
serum. To this a 1 mL aliquot of 98% acetyl chloride 
(Aldrich Chemical Co.) and a 50 microL aliquot of 27% ZnC12 
in glacial acetic acid were added. The vial was capped, and 
on shaking the mixture a protein precipitate was formed. 
The vial was placed in a 67° C water bath and incubated for 
8 minutes. The product of the reaction is an orange or 
reddish-orange colored solution. The vial was removed and 
cooled in a room temperature water bath. The contents were 
transferred to a 1.7 mL polypropylene centrifuge tube, 
sealed, and centrifuged at 15,000 rpm for two minutes. 
The supernate was transferred to a 1 em. pathlength 
cuvet and placed in the cell compartment of the Hitachi 100-
80-A spectrophotometer. The visible absorption spectrum was 
run from 700 nm to 400 nm. The spectrum was corrected for 
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solution blank and instrument baseline by subtracting this 
spectrum, which was saved in the computer memory of the 
spectrophotometer, from the spectrum for the colored product 
of the Chugaev reaction. A typical printout of the net 
spectrum for whole serum cholesterol and the three fractions 
is shown in Figure 1. Since the Chugaev reagent combines 
with cholesterol in all of its biological environments in 
human serum, the spectrum is the weighted aggregate of the 
contributions from cholesterol bonded to the three major 
lipoprotein fractions, namely, the VLDL-C, LDL-C, and HDL-C. 
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Analysis of the Spectrum 
for the Fractions 
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In the Allain-Trinder enzymatic method the colors 
produced for the three fractions are identical. Because of 
this, separations are necessary before the distribution of 
cholesterol among the fractions can be determined. The 
success of the Chugaev method depends entirely upon the fact 
that the colors, and therefore the absorption spectra for 
the products of the reactions with cholesterol in each of 
the fractions, differ. It is proposed that this will enable 
the researcher to determine the total distribution in one 
experiment. 
In order to substantiate this hypothesis, the reaction 
was run on lipoprotein fractions that were (a) separated by 
ultrafiltration and commercially available from Sigma 
Chemical Company and (b) separated by ultracentrifugation 
and made available by the lipoprotein research laboratory of 
the Oklahoma Medical Research Foundation. The absolute 
purity of the fractions as standard reference materials was 
not guaranteed, but the samples are among the best that are 
available. Absorption spectra for each of the fractions are 
in fact sign1ficantly different as shown in Figure 1, and it 
is theoretically possible to use these differences to 
quantitatively calculate the amounts of each fraction in a 
total serum cholesterol spectrum. The remaining problem is 
to find a mathematical model that will fit the spectra for 
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the weighted contributions from each cholesterol fraction to 
the total spectrum of the whole. 
Mathematical Model 
The first assumption made was that the contributions 
from each of the fractions are additive at all wavelengths 
from 700 nm to 400 nm. Therefore, the absorption at 
any wavelength is a weighted sum of three parts. 
According to the theory of light absorption, also known 
as Beer's Law (47), the magnitude of the absorption (A) is 
related directly to the absorption strength (E), the 
concentration of the absorbing molecule in the solution (C), 
and to the pathlength of the solution in the cuvet (d) and 
is given by the simple equation 
A = ECd 
(Equation 1) 
The quantity E depends upon the molecular structure of 
the absorbing compound and cannot be calculated. It is 
usually measured from the slope of a linear plot of A versus 
cat constant d (47). At every wavelength, therefore, there 
will be three absorption terms: 
A = AVLDL-C + ALDL-C + AHDL-Ct 
and if these are substituted by the Beer's Law equivalents, 
the total absorption is given by the equation 
A = EVLDL-CCVLDL-cd + ELDL-cCLDL-cd + Eaoi-cCHDL-cd 
(Equat~on 2) 
To solve the problem, the E values must be known. 
However, because the fractions are not pure, accurate values 
can not be determined from the linear dependencies of A 
versus c. Consequently, E values must be estimated 
empirically, and in order to determine the unknown 
concentrations CLDL-c' CVLDL-c and CHDL-c' absorption 
measurements must be made at three different wavelengths. 
Overall therefore, nine E values are required to determine 
the distribution of cholesterol among the three fractions. 
The simplest mathematical model is to solve three 
simultaneous linear equations. 
Selection of Wavelengths and 
Determination of E Values 
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In theory, the optimum wavelengths to use for 
quantitative work are turning points in the absorption 
spectrum, because errors in the measurements are minimized. 
These are often distinguished as maxima or minima in 
absorption values. The wavelengths selected for the 
mathematical model were the maximum at 518 nm, the minimum 
at 450 nm, and the maximum at 420 nm, as shown in Figure 1. 
The wavelengths are typical of the turning points for the 
spectra for all serum samples, although they do not exactly 
correspond with the turning points for all of the fractions 
individually. 
For a solution of known concentration {C), and known 
pathlength (d), the absorption measurements are directly 
proportional to theE values {Equation 2). In all of this 
work d = 1 em. Therefore, if an E value can be estimated at 
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any one wavelength, then it can be calculated at all other 
wavelengths in the spectrum. The assumption was made that 
at the major maximum at 518 nm the E values for VLDL-C, LDL-
c, and HDL-C were equal. Using this value and the spectra 
for each of the fractions, the six E values could be 
calculated at the remaining two wavelengths for each 
fraction. Substituting the single value for E into the 
absorption equation, Equation 2, at 518 nm, the expression 
can be rewritten as: 
A = E [ CVLDL-C + CLDL-C + CHDL-C] = E ( TC) • 
Given a value for TC and a measured A value for a serum 
sample, E at 518 nm can be determined. 
In order to calibrate the spectrum and to determine E 
at 518 nm, measured TC values from Roche Laboratories were 
used. Statistically a single value cannot be used for 
calibration because of the random errors associated with a 
single measurement. Consequently, the ratios of measured A 
values divided by the TC values, as determined by Roche, for 
the 77 subject samples were averaged. The value for E at 
518 nm was determined to be 3.00± 0.10 mA.dLfmg. This value 
is used as the basis for the calculation of the other E 
values for all fractions using the spectrum data for each. 
For instance, ELDL-c at 450 nm is equal to 
{ALDL-C(450)fALDL-C(51S)}[ELDL-C(518)] 
The resultant E values in mA.dL/mg are: 
FRACTIONS 
EslS 
E450 
E420 
VLDL-C 
3.00 
1.35 
2.41 
LDL-C 
3.00 
1.25 
1.25 
HDL-C 
3.00 
1.97 
2.52 
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and the corresponding linear simultaneous equations required 
for the mathematical model are: 
A518 = 3.00 CVLDL-C + 3.00 CLDL-C + 3.00 CaDL-e 
A450 = 1.35 CVLDL-C + 1.25 CLDL-C + 1.97 CaDL-C 
A420 = 2.41 CVLDL-C + 1.25 CLDL-C + 2.52 CaDL-e 
The E values obtained in this way are not exact because 
the separations of the individual fractions by either 
ultracentrifugation or ultrafiltration are not exact. This 
is the major obstacle to accurate measurements of serum 
cholesterol fractions. Consequently in subsequent 
comparisons between results determined by the Chugaev and 
the enzymatic methods, additional minor adjustments in the E 
values might be necessary. While this may affect the 
accuracy of the measurement it will not affect the level of 
precision that can be achieved with the Chugaev method. 
Precision is established by the reproducibility of the 
spectrum for the serum samples and not by the mathematical 
model or the individual E values. 
The A values were measured for each serum included in 
the study at all three wavelengths. Data were entered into 
a Wingztm software spreadsheet for the Macintosh computer 
which includes an algorithm program to solve the three 
simultaneous linear equations for the amounts of each 
fraction in mgjdL. 
Statistical Analysis 
The data collected in the study were analyzed by the 
following methods: 
1. Pearson r between the pairs of scores for each 
dependent variable was calculated. 
2. The percent of each fraction to total cholesterol 
for each subject and the average percent for each fraction 
was calculated. 
3. The values from one method (Chugaev) were 
subtracted from the values of the other method (Allain-
Trinder) and the differences were averaged. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
The purpose of this study was to test the hypothesis 
that there would be no significant difference in the LDL-C 
values directly measured by the Chugaev method and 
calculated values derived from the Allain-Trinder enzymatic 
method. 
Each of the 77 subjects requested a lipid 
profile/analysis from the Oklahoma State University Wellness 
Center during September, October, and November of 1991. 
They were instructed to report to the Wellness Center having 
fasted for at least 12 hours. 
The data collected in the study were analyzed by the 
following methods: 
1. Pearson r between the pairs of scores for each 
dependent variable was calculated. 
2. The percent of each fraction to total cholesterol 
for each subject was calculated, and the average percent of 
each fraction to total cholesterol was calculated. 
3. The values from one method (Chugaev) were 
subtracted from the values of the other method (Allain-
Trinder) and the differences were averaged. 
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Results 
The raw data by subject number are given in Appendix B. 
The normative data are given in Table I. 
Variable 
TC 
HDL-C 
VLDL-C 
LDL-C 
TC = 
HDL-C = 
VLDL-C = 
LDL-C = 
TABLE I 
NORMATIVE DATA 
Allain-Trinder Chugaev 
Mean SD SE Mean 
<in mg/dLl (in 
200.5 36.5 4.2 198.2 
46.0 12.9 1.5 45.8 
21.9 10.7 1.2 17.1 
131.9 32.5 3.7 135.4 
total cholesterol 
high density lipoprotein cholesterol 
very low density lipoprotein cholesterol 
low density lipoprotein cholesterol 
Results of Pearson r Analysis 
SD 
mg/dLl 
41.3 
14.2 
7.8 
35.2 
The results of the Pearson r analysis are given in 
SE 
4.7 
1.6 
0.9 
4.0 
Table II. The correlations between the two methods for two 
of the variables were significant (p < .01) while the other 
I 
two were not. 
TABLE II 
CORRELATION COEFFICIENTS* 
n = 77 
Allain-Trinder TC vs. Chugaev TC 
Allain-Trinder HDL-C vs. Chugaev HDL-C 
42 
.9464 
.0059 
Allain-Trinder VLDL-C vs. Chugaev VLDL-C -.0158 
Allain-Trinder LDL-C vs. Chugaev LDL-C .8555 
* r = .22 with p < .05 
r = .29 with p < .01 
Results of Percent Fraction Analysis 
The results of the percent fraction analysis are given 
in Table III. 
TC 
HDL-C 
VLDL-C 
LDL-C 
TC = 
HDL-C = 
VLDL-C = 
LDL-C = 
TABLE III 
CHOLESTEROL FRACTION AS A PERCENT 
OF TOTAL CHOLESTEROL 
Chugaev Allain-Trinder 
Mean 
Cin mg/dL) 
200.5 
46.0 
21.9 
131.9 
(23.7) 
(10.8) 
(65.2) 
total cholesterol 
Mean 
(in mg/dL) 
198.2 
45.8 
17.1 
135.4 
high density lipoprotein cholesterol 
very low density lipoprotein cholesterol 
low dens1ty lipoprotein cholesterol 
(23.7) 
( 8.5) 
(67.6) 
Results of Difference Analysis 
The results of the difference analysis are given in 
Table IV. The frequency distributions for the difference 
analyses are given in Tables V, VI, VII, and VIII. 
TABLE IV 
MEAN DIFFERENCE BETWEEN METHODS 
(ALLAIN-TRINDER MINUS CHUGAEV) 
TC 
VLDL-C 
HDL-C 
LDL-C 
2.299 mgfdL 
4.857 mgfdL 
.286 mgfdL 
-3.519 mgfdL 
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TABLE V 
FREQUENCY DISTRIBUTION FOR DIFFERENCE 
{ALLAIN-TRINDER TC MINUS CHUGAEV TC) 
n = 77 
Value Freguency Percent 
{in mgjdL) 
-28.00 1 1 
-25.00 1 1 
-24.00 1 1 
-18.00 2 3 
-17.00 1 1 
-14.00 2 3 
-13.00 1 1 
-12.00 1 1 
-11.00 2 3 
- 9.00 4 5 
- 8.00 3 4 
- 7.00 4 5 
- 6.00 2 3 
- 5.00 1 1 
- 3.00 6 8 
- 2.00 1 1 
- 1.00 2 3 
.00 1 1 
1. 00 2 3 
2.00 1 1 
3.00 4 5 
4.00 3 4 
6.00 1 1 
7.00 4 5 
8.00 4 5 
9.00 2 3 
10.00 2 3 
12.00 2 3 
14.00 1 1 
15.00 1 1 
16.00 2 3 
18.00 2 3 
19.00 1 1 
20.00 1 1 
21.00 2 3 
22.00 1 1 
24.00 1 1 
25.00 1 1 
31.00 1 1 
34.00 1 1 
39.00 1 1 
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Mean 2.299 
SD 13.624 
TABLE VI 
FREQUENCY DISTRIBUTION FOR DIFFERENCE 
(ALLAIN-TRINDER VLDL-C MINUS 
CHUGAEV VLDL-C) 
n = 77 
Value Freguency Percent 
(in mgfdL) 
-20.00 1 1 
-15.00 2 3 
-13.00 1 1 
-12.00 2 3 
-11.00 2 3 
-10.00 2 3 
- 8.00 3 4 
- 7.00 1 1 
- 6.00 3 4 
- 5.00 2 3 
- 4.00 3 3 
- 3.00 4 5 
- 2.00 3 4 
- 1.00 1 1 
.00 4 5 
1. 00 2 3 
2.00 1 1 
3.00 4 5 
4.00 4 5 
5.00 2 3 
6.00 1 1 
7.00 1 1 
8.00 3 4 
9.00 2 3 
10.00 2 3 
11.00 3 4 
13.00 1 1 
14.00 1 1 
16.00 2 3 
17.00 1 1 
19.00 1 1 
21.00 2 3 
25.00 2 3 
27.00 2 3 
29.00 1 1 
31.00 2 3 
34.00 1 1 
38.00 1 1 
39.00 1 1 
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Mean 4.857 
SD 13.371 
TABLE VII 
FREQUENCY DISTRIBUTION FOR DIFFERENCE 
(ALLAIN-TRINDER HDL-C MINUS 
CHUGAEV HDL-C) 
n = 77 
Value F;t:egyency: Pe;t:cent 
(l.n mg/dL) 
-43.00 1 1 
-42.00 1 1 
-40.00 1 1 
-29.00 1 1 
-28.00 2 3 
-26.00 2 3 
-25.00 1 1 
-24.00 1 1 
-23.00 1 1 
-19.00 1 1 
-18.00 1 1 
-17.00 1 1 
-16.00 1 1 
-15.00 3 4 
-13.00 1 1 
-12.00 1 1 
-11.00 1 1 
-
8.00 1 1 
- 7.00 1 1 
-
6.00 4 5 
- 4.00 3 4 
- 3.00 1 1 
- 2.00 2 3 
- 1.00 1 1 
.00 5 6 Mean .286 
1.00 4 5 so 19.144 
2.00 1 1 
3.00 2 3 
4.00 3 4 
5.00 1 1 
6.00 2 3 
7.00 2 3 
8.00 1 1 
11.00 2 3 
12.00 1 1 
14.00 2 3 
17.00 1 1 
18.00 3 4 
19.00 1 1 
20.00 1 1 
21.00 1 1 
22.00 1 1 
24.00 2 3 
26.00 2 3 
27.00 2 3 
28.00 1 1 
47.00 1 1 
59.00 1 1 
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TABLE VIII 
FREQUENCY DISTRIBUTION FOR DIFFERENCE 
(ALLAIN-TRINDER LDL-C MINUS 
CHUGAEV LDL-C) 
n = 77 
Value Fregyenc:t: Percent 
(~n mg/dL) 
-48.00 1 1 
-45.00 1 1 
-33.00 1 1 
-29.00 1 1 
-26.00 2 3 
-25.00 1 1 
-24.00 2 3 
-23.00 4 5 
-21.00 3 4 
-20.00 1 1 
-19.00 2 3 
-18.00 2 3 
-17.00 1 l 
-16.00 2 3 
-15.00 1 1 
-14.00 2 3 
-11.00 1 1 
-10.00 1 1 
- 9.00 3 4 
- 8.00 1 1 
- 7.00 3 4 
- 6.00 2 3 
- 5.00 1 1 
- 4.00 1 1 Mean -3.519 
-
3.00 3 4 SD 18.387 
- 2.00 1 1 
- 1.00 1 1 
.00 1 1 
1.00 2 3 
2.00 1 1 
3.00 1 1 
4.00 1 1 
6.00 2 3 
7.00 1 1 
8.00 3 4 
10.00 1 1 
12.00 2 3 
13.00 1 1 
14.00 2 3 
15.00 3 4 
18.00 1 1 
19 00 1 1 
20.00 1 1 
21.00 1 1 
24.00 1 1 
25.00 1 1 
28.00 1 1 
29 00 1 1 
30.00 1 1 
35.00 1 1 
37 00 1 1 
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Discussion of Results 
This study compared the results from the Chugaev method 
of directly measuring the LDL-C fraction of serum 
cholesterol with the results obtained by Roche Biomedical 
Laboratories, which used the Allain-Trinder enzymatic method 
of calculating LDL-C levels. The values determined by both 
methods for TC and LDL-C were significantly correlated. 
Since LDL-C was the primary focus of the study, these 
results are encouraging. As reported by the Laboratory 
Standardization Panel (LSP) of the National Cholesterol 
Education Program (NCEP), serious inaccuracies exist in the 
measured amounts of TC in human serum reference standards 
(28). Considering only one trial was performed by each 
method, the similarities in values are noteworthy. Without 
reproducibility studies, it is not possible to comment on 
the accuracy or bias of the measurements of either method. 
More recent work on reproducibility with the Chugaev method 
is showing promising results (35). 
It was expected that the TC values would correlate 
because E at 518 is calculated from Roche Laboratories 
numbers. The fact that 1t does so for so many individuals 
attests to the fact that the Chugaev method is a valid and 
reliable method. The good correspondences between the 
population means is further support for the model used to 
calculate the fractions. 
In the course of the investigation, the values 
determined for HDL-C and VLDL-C by the two methods were also 
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compared. The values determined for HDL-C and VLDL-C did not 
correlate significantly. Although the reasons for this 
outcome cannot be explained totally, there are several 
possible explanations. 
The estimation technique used by Roche Laboratories 
relies on the accuracy of the cholesterol and TG assays, the 
HDL-C precipitation, and the mathematical formula used to 
estimate the VLDL-C concentration. The accuracy of the 
Friedewald formula, and therefore the estimation of LDL-C is 
particularly dependent upon the validity of the assumption 
that VLDL-C can be estimated by TG/5. DeLong et al (12) 
found that in fasting samples this has been found to be 
approximately so when TG value does not exceed 400 mg/dL, 
but in some circumstances the expression 0.16 x TG leads to 
a more accurate estimate of VLDL-C, and thereby calculation 
of LDL-C. A study by McNamara et al (36) compared several 
VLDL-C estimation methods (TG/4- TG/8). No single best 
estimation factor emerged, but use of the factors TG/5 to 
TG/6 generally yielded the h1ghest percentages. In light of 
evidence that TG/5 is not always an accurate estimate of 
VLDL-C, it is possible that the values determined by Roche 
Laboratories for this fraction are not accurate. 
HDL-C measurements require two kinds of manipulations: 
the isolation of the HDL-C containing fraction from plasma 
or serum, and then the measurement of cholesterol in this 
fraction. Some of the analytic variability encountered in 
HDL-C measurement is related to the difficulty of the 
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precipitation step employed to obtain a pure sample of HOL-
e. This variability is sufficiently great that some authors 
have suggested that HDL-C measured in an individual patient 
may not be useful in the primary assessment of risk or 
change in risk after institution of therapy (6). In the 
method used by Roche Laboratories, LDL-C and VLDL-C were 
precipitated from serum with dextran sulfate. Cholesterol 
remaining in the supernatant solution can be considered to 
represent HDL-C, if sedimentation of LDL-C and VLDL-C is 
complete and no HDL-C has precipitated. The cholesterol 
content of the supernate, and hence the HDL-C, was measured 
by the enzymatic method of Allain-Trinder with the Olympus 
Model 5031 analyzer. It is possible, therefore, that 
differences in the values determined for HDL-C may have 
resulted because precipitation of LDL-C and VLDL-C in the 
Allain-Trinder method was not selective or complete. 
A striking feature of the HDL-C and VLDL-C values is 
the closeness of the means without significant correlation. 
The frequency distributions for these fractions provide an 
explanation for this observation. For each individual 
comparison, there are some extremely wide variations of 
values. For example, the mean difference between HDL-C 
values was .286, but the individual differences ranged from 
-43.00 to +59.00. 
Approximately 98 percent of all laboratories now 
participating in the College of American Pathologists 
proficiency testing survey report the use of enzymatic 
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procedures (56) used by Roche Laboratories. Although not 
without limitations, this procedure is reasonably reliable, 
and represents a well-accepted method. It was expected that 
the values determined by the Chugaev method would not be 
significantly different from the values determined by the 
Allain-Trinder enzymatic method. It is clear from the 
excellent TC and LDL-C correlations that the chemistry of 
Chugaev method is able to discriminate among the three 
cholesterol fractions in a single experimental measurement; 
that the three fractions are being determined 
quantitatively; and that the simple mathematical model 
works. The coefficients in the mathematical model described 
in Chapter 3 were manipulated to come as close to the values 
determined by Roche Laboratories as possible. Once pure 
samples of all fractions are available and measured, the 
conventional Beer's law calibration curves of A vs. 
concentration of fraction can be used to give the nine E 
coefficients without resorting to an empirical fit. 
There are also several practical advantages to the 
Chugaev method over the enzymatic method, including: {1) a 
smaller volume of blood is required for a full lipid 
profile; (2) the three fractions are measured, and in a 
direct manner; (3) only one test rather than three is 
required to determine LDL-C. 
CHAPTER V 
SUMMARY, FINDINGS, CONCLUSIONS 
AND RECOMMENDATIONS 
Summary 
The guidelines recently published by the NCEP for the 
detection, evaluation, and treatment of high blood 
cholesterol in adults emphasize the reduction of high levels 
of LDL-C. Reasonably accurate determination of LDL-C is an 
important aim in view of the significance of this measure as 
a risk factor for coronary heart disease. This study 
compared the Chugaev method for direct measurement of LDL-C 
with the well-accepted Allain-Trinder enzymatic method in 
which LDL-C levels are calculated from measured total, VLDL-
c, and HDL-C levels. 
The data collected in the study were analyzed by the 
following methods: 
1. Pearson r between the pairs of scores for each 
dependent variable was calculated. 
2. The pe~cent of each fraction to total cholesterol 
for each subject and the average percent for each fraction 
was calculated. 
52 
3. The values from one method (Chugaev) were 
subtracted from the values of the other method (Allain-
Trinder) and the differences were averaged. 
Findings 
Based on the hypothesis stated and the limits of this 
study, the data yielded the following findings: 
1. There was no significant diffe~ence in the values 
for TC and LDL-C as determined by the two methods. 
2. Although the mean values for VLDL-C and HDL-C 
levels measured by both methods for a population of 77 
volunteers were in excellent agreement, significant 
differences occurred between the levels determined for 
individual members of the population. The statistical 
significance of this result is not clear at this time. 
Conclusions 
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In consideration of the results the conclusion that the 
Chugaev method is able to measure LDL-C as accurately as the 
widely accepted enzymatic method seems warranted. 
Recommendations 
Based on the data collected in this study, it is 
evident that additional research is needed to establish the 
Chugaev method as a viable alternative for the well 
established enzymatic method. 
Until pure fraction samples become available it is not 
possible to address the accuracy in the measurements. In 
the meantime, extensive reproducibility studies need to be 
made in order to compare the relative precisions attainable 
by both procedures. These investigations should include 
various population groups, by age, race, and gender. There 
is good reason to believe that high triglyceride levels are 
not a deterent to direct measurement of VLDL-C by the 
Chugaev method and patients with hypertriglyceridemia might 
benefit greatly from additional lipid profile information. 
The following recommendations are also presented as a 
result of this study as means of refining the Chugaev 
procedure: 
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1. Increase the volume of serum to reduce inaccuracies 
due to measurement error. 
2. Improve care in storage to keep reagents dry. If 
they get wet in storage, the reagent mix is altered and they 
produce a different chemical reaction. 
3. Run a baseline before every measurement to reduce 
error due to instrument drift. 
A SELECTED BIBLIOGRAPHY 
1. Abell, L.L., Levy, B.B., Brodie, B.B., Kendall, F.E. 
"A Simplified Method for the Estimation of Total 
Cholesterol in Serum and Demonstration of its 
Specificity." J. Biol. Chem. 195 (1952), pp. 357-
366. 
2. Allain, c.c., Poon, L.S., Chan, C.S.G., et al. 
"Enzymatic Determination of Total Serum 
Cholesterol." Clin Chem 20:4 (1974), pp. 470-475. 
3. American Medical Association. Home Medical 
Encyclopedia. New York: Random House, 1989. 
4. Assmann, G., Schriewer, H., Schmitz, G., and Hagele, 
E.O. "Quantification of High-Density-Lipoprotein 
Cholesterol by Precipitation with Phosphotungstic 
Acidfmgcl2 . 11 Clin Chem 29:12 (1983), pp. 2026-
2030. 
5. Barr, D.P., Russ, E.M., Eder, H.A. "Protein-Lipid 
Relationships in Human Plasma II. In 
Atherosclerosis and Related Conditions." 
Am J Med 11 (1951), pp. 480-493. 
6. Blank, D.W., Hoeg, J.M., Kroll, M.H., Ruddel, M.E. 
"The Method of Determination Must be Considered 
in Interpreting Blood Cholesterol Levels." JAMA 
256:20 (1986), pp. 2867-2870. 
7. Bookstein, L., Gidding, s.s., Donovan, M., Smith, F.A., 
"Day-to-Day Variability of Serum Cholesterol, 
Triglyceride, and High-Density Lipoprotein 
Cholesterol Levels." Arch Intern Med 150 (1990), 
pp. 1653-1656. 
8. Castelli, W.P., Garrison, R.J., Wilson, P.W.F., et al. 
"Incidence of Coronary Heart Disease and 
Lipoprotein Cholesterol Levels: The Framingham 
Study." JAMA. 256:20 (1986), pp. 2835-2838. 
9. Chugaev, L., Gastev, A. Ber 42 (1910), p. 4631. 
10. Consensus Conference. "Lowering Blood Cholesterol to 
Prevent Heart Disease." JAMA 253:14 (1985), pp. 
2080-2086. 
55 
11. Dalen, J.E. "Lowering Serum Cholesterol. It is Time 
to Proceed" Arch Intern Med 148 {1988}, pp. 34-
35. 
56 
12. DeLong, D.M., DeLong, E.R., Wood, P.O., et al. "A 
Comparison of Methods for the Estimation of Plasma 
Low- and Very Low-Density Lipoprotein 
Cholesterol." JAMA 256:17 {1986), pp. 2372-2377. 
13. Demacker, P.N., Hijmans, A.G., Brenninkmeijer, B.J., et 
al. "Five Methods for Determining Low-Density 
Lipoprotein Cholesterol Compared." Clin Chem. 
30:11 {1984), pp. 1797-1800. 
14. Expert Panel. "Report of the National Cholesterol 
Education Program Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol 
in Adults." Arch Intern Med 148 {1988}, pp. 36-69. 
15. Fardy, P.S., Yanowitz, F.G., Wilson, P.K., Cardiac 
Rehabilitation, Adult Fitness, and Exercise 
Testing. Philadelphia: Lea & Febiger, 1988. 
16. Finley, P.R., Schifman, R.B., Williams, R.J., Lichti, 
D.A. "Cholesterol in High-Density Lipoprotein: Use 
of Mg(II)/Dextran Sulfate in its Enzymic 
Measurement." Clin Chem 24:6 (1978), pp. 931-933. 
17. Friedewald, W.T., Levy, R. I., Fredrickson, o.s., 
"Estimation of the Concentration of Low-Density 
Lipoprotein Cholesterol in Plasma, Without Use of 
The Preparative Ultracentrifuge." Clin Chem 18:6 
{1972}, pp. 449-501. 
18. Frohlich, J.J., Pritchard, P. H. "The Clinical 
significance of Serum High Density Lipoproteins." 
Clin Biochem 22 {1989), pp. 417-423. 
19. Gordon, D.J., Probstfield, J.L., Garrison, R.J., et al. 
"High-Density Lipoprotein Cholesterol and 
Cardiovascular Disease: Four Prospective 
American Studies." circulation 79:1 {1989), pp. 
8-15. 
20. Gordon, D.J., Rifkind, B.M., "High-Density Lipoprotein 
- The Clinical Implications of Recent Studies." 
New Engl J Med 321:19 {1989), pp. 1311-1316. 
21. Gordon, T., Castelli, W.P., Hjortland, M.C., et al. 
"High Density Lipoprotein as a Protective Factor 
Against Coronary Heart Disease." Am J Med. 62 
(1977} 1 PP• 707-714. 
22. Gordon, T., Kannel, W.B., Castelli, W.P., Dawber, T.R. 
"Lipoproteins, Cardiovascular Disease and Death. 
The Framingham Study." Arch Intern Med 141 
(1981), pp. 1128-1131. 
23. Green, M.S., Heiss, G., Rifkind, B.M., et al. "The 
Ratio of Plasma High-Denisty Lipoprotein 
Cholesterol to Total and Low-Density Lipoprotein 
Cholesterol: Age-Related Changes and Race and 
sex Differences in Selected North American 
Populations. The Lipid Research Clinics Program 
Prevalence Study." Circulation 72:1 (1985), pp. 
93-104. 
24. Grundy, S.M. "Cholesterol and Coronary Heart Disease: 
A New Era." JAMA 256:20 (1986), pp. 2849-2858. 
25. Grundy, S.M., DeWitt, s. G., Rifkind, B.M., Cleeman, 
J.I. "The Place of HDL in Cholesterol Management." 
Arch Intern Med 149 (1989), pp. 505-510. 
26. Hanel, H.K., Dam, H. "Determination of Small Amounts 
of Total Cholesterol by the Tschugaeff Reaction 
with a Note of the Determination of Lathosterol." 
Acta Chemica Scandinavica 9:4 (1955) pp. 677-
682. 
27. Katch, F.I., McArdle, W.D. Nutrition, Weight Control, 
and Exercise. Philadelphia: Lea & Febiger, 
1988. 
28. Laboratory Standardization Panel, National Cholesterol 
Education Program. "Current Status of Blood 
Cholesterol Measurement in Clinical Laboratories 
in the United States." Clin Chem 34:1 (1988), pp. 
193- 201. 
29. Lavie, C.J., O'Keefe, J. H., Blonde, L., Gau, G.T., 
"High-density Lipoprotein Cholesterol: 
Recommendations for Routine Testing and 
Treatment." Postgrad Med 87:7 (1990), pp. 
36, 38-44, 47, 51. 
30. Levy, R.I. "Cholesterol and Cardiovascular Disease: 
No Longer Whether, but Rather When, in Whom, and 
How?" Circulation 72:4 (1985), pp. 686-691. 
31. Lipid Research Clinics Program. "The Lipid Research 
Clinics Coronary Primary Prevention Trial 
Results. I. Reduction in Incidence of Coronary 
Heart Disease." JAMA 251:3 (1984), pp. 351-
362. 
57 
32. Lipid Research Clinics Program. "The Lipid Research 
Clinics Coronary Primary Prevention Trial 
Results. II. The Relationship of Reduction in 
Incidence of Coronary Heart Disease to 
Cholesterol Lowering." JAMA. 251 (1984), pp. 
365-374. 
33. Lipid Research Clinics Program Epidemiology Committee. 
"Plasma Lipid Distributions in Selected North 
American Populations: The Lipid Research 
Clinics Program Prevalance study." Circulation 
60:2 (1979) I PP· 427-439. 
34. Lopes-Virella, M.F., Stone, P., Ellis, S., Colwell, 
J.A. "Cholesterol Determination in High-Density 
Lipoproteins Separated by Three Different 
Methods." Clin Chem 23:5 {1977), pp. 882-884. 
35. Lucas, Edralin, personal communication, February 3, 
1992. 
36. McNamara, J.R., Cohn, J.D., Wilson, P.W.F., Schaefer, 
E.J. "Calculated Values for Low-Density 
Lipoprotein Cholesterol in the Assessment of Lipid 
Abnormalities and Coronary Disease Risk." 
Clin Chem 36:1 (1990), pp. 36-42. 
37. MEDCOM Learning Systems. Atherosclerosis. New York: 
MEDCOM, Inc., 1974. 
38. Mogadam, M., Ahmed, s.w., Mensch, A.H., Godwin, I.D. 
"Within-Person Fluctuations of Serum Cholesterol 
and Lipoproteins." Arch Intern Med 150 (1990), 
pp. 1645-1648. 
39. Morbidity and Mortality Weekly Report, "Years of Life 
Lost from Cardiovascular Disease." JAMA 256:20 
( 1986) 1 P• 2794 • 
58 
40. Multiple Risk Factor Intervention Trial Research Group. 
"Multiple Risk Factor Intervention Trial. Risk 
Factor Changes and Mortality Results." JAMA 
248:12 (1982), pp. 1465-1477. 
41. National Cholesterol Education Program. Report of the 
Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults. NIH 
Publication No. 89-25, 1989. 
42. National Cholesterol Education Program. Report of the 
Expert Panel on Population Strategies for Blood 
Cholesterol Reduction, Executive Summary. NIH 
Publication No. 90-3047, 1990. 
43. National Institutes of Health. "Facts about Blood 
Cholesterol." NIH Publication No. 90-2696, 1990. 
44. National Institutes of Health. Recommendations for 
Improving Cholesterol Measurement. NIH 
Publication No. 90-2964, 1990. 
45. Nieman, D.C. Fitness and Sports Medicine: An 
Introduction. Palo Alto, California: Bull 
Publishing Company, 1990. 
46. Rosenfeld, L. "Lipoprotein Analysis: Early Methods in 
the Diagnosis of Atherosclerosis." Arch Pathol 
Lab Med 113 (1989), pp. 1101-1110. 
47. Skoog, D.A., West, D.M., Holler, F.J. Fundamentals of 
Analytical Chemistry. 6th edition, Ft. Worth: 
Saunders College Publishing, 1992. 
48. Stamler, J., Wentworth, D., Neaton, J.D. "Is 
Relationship Between Serum Cholesterol and Risk 
of Premature Death from Coronary Heart Disease 
Continuous and Graded?" JAMA 256:20 (1986), pp. 
2823-2828. 
49. Steele, B.W., Keohler, D.F., Azar, M.M., et al. 
"Enzymatic Determinations of Cholesterol in High-
Density-Lipoprotein Fractions Prepared by a 
Precipitation Technique." Clin Chern 22:1 (1976), 
pp. 98-101. 
50. Stein, E.A. "Lipid Risk Factors and Atherosclerosis: 
What do we Measure?" Scand J Clin Lab Invest 198 
(1990), pp. 3-8. 
51. Superko, H.R., Bachorik, P.S., Wood, P.O. "High 
Density Lipoprotein Cholesterol Measurements, A 
Help or Hinderence in Practical Clinical 
Medicine." JAMA 256 (1986), pp. 2714-2717. 
52. Superko, H. R. , Wood, P. D. , Haskell, W. L. "Coronary 
Heart and Risk Factor Modification: Is There a 
Threshold?" Am J Med 78 (1985), pp. 826-838. 
53. Thomas, C.L. Taber's Cyclopedic Medical Dictionary. 
Philadelphia: F.A. Davis co., 1975. 
54. Tietz, N.W. Fundamentals of Clinical Chemistrv. 3rd 
edition, Philadelphia: W.B. Saunders Company, 
1987. 
55. Trinder, P. "Determination of Glucose in Blood using 
Glucose Oxidase with an Alternative oxygen 
Acceptor." Ann Clin Biochem 6 (1969), p. 24. 
59 
56. Warnick, G.R. "Laboratory Measurement of Lipid and 
Lipoprotein Risk Factors," Scand J Clin Lab 
Invest 198 (1990), pp. 9-19. 
57. Warnick, G.R., Albers, J.J., "A Comprehensive 
Evaluation of the Heparin-Manganese Precipitation 
Procedure for Estimating High Density Lipoprotein 
Cholesterol." J. Lipid Res. 19 (1978), pp. 65-76. 
58. Warnick, G.R., Benderson, J., Albers, J.J. "Dextran 
Sulfate-Mg2+ Precipitation Procedure for 
Quantitation of High-Density-Lipoprotein 
Cholesterol." Clin Chem 28:6 (1982), pp. 1379-
1387. 
59. Warnick, G.R., Cheung, M.c., Albers, J.J. "Comparison 
of Current Methods for High-Density Lipoprotein 
Cholesterol Quantitation." Clin Chem 25:4 (1979), 
pp. 596-604. 
60. Warnick, G.R., Knopp, R.H., Fitzpatrick, v., Branson, 
L. "Estimating Low-Density Lipoprotein 
Cholesterol by the Fr1edewald Equation is Adequate 
for Classify1ng Patients on the Basis of National 
Recommended Cutpoints." Clin Chem 36:1 (1990), pp. 
15-19. 
61. Westgard, J.O., Petersen, P.H., Wiebe, D.A. 
"Laboratory Process Specifications for Assuring 
Quality in the u.s. National Cholesterol 
Education Program." Clin Chem 37:5 (1991), pp. 
656-661. 
62. Whitney, E.N., Hamilton, E.M.N. Understanding 
Nutrition. 4th Edition, St. Paul: West 
Publishing Company, 1987. 
63. Wynder, E.L., Field, F., Haley, N.J. "Population 
Screening for Cholesterol Determination: A Pilot 
Study." JAMA 256:20 (1986), pp. 2839-2842. 
64. Zak, B. "Cholesterol Methodologies: A Review." 
Clin Chem 23:7 (1977), pp. 1201-1214. 
60 
APPENDIXES 
61 
APPENDIX A 
INFORMED CONSENT 
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OSU WELLNESS CENTER 
INFORMED CONSENT FORM 
BLOOD TESTING 
Explanation of Test 
The blood test you are about to undergo IS part of the Oklahoma State Umversity 
Wellness Program. The test mcludes selected blood vanables analyzed from the fingerstick 
method or from a venous sample. 
It will be determmed, pnor to testmg, that tlns test IS appropnate and safe for you. 
All testing will be conducted by tramed personnel and procedures will be explamed to your 
sansfaction at the outset. 
Possible Risks 
The potential nsks assOCiated wtth the vempuncture/fingersnck are (1) 
Verupuncture/fingersnck may cause some pam or dtscomfort. The exact amount, tf any, 
will be dependent upon mdtvtdual preconcepnons and pam threshold levels (2) Possible 
hematoma (brmsmg) at the verupuncture/fingerstick Site following the procedure. The 
occurrence or non-occurrence will be dependent upon bleedmg/coagulation nmes and 
adherence to mstruct:J.ons pertammg to holdmg a cotton ball agamst the 
verupuncture/fingerstick site, wtth pressure, for five mmutes followmg extracnon of the 
needle or followmg the fingersnck. (3) Shght nsk of mfecnon. Any break m the mtegnty 
of the skm IS associated wtth a small degree of nsk mfection. However, tf drrections are 
followed the nsk IS very small. 
Consent by Subject 
The mformation which 1s obtamed will be treated as pnvtleged and confidential and 
will not be released or revealed to anyone wtthout your express consent Information Will, 
however, be treated m an aggregate manner to provtde group Information. In addtnon, tf 
mdtcated, a small amount of the blood drawn may be used for research m alternat:J.ve 
cholesterol testmg. 
I have read the foregomg, I understand It, and any questions winch may have 
occurred to me have been answered to my satisfaction. 
Date-------
Su~ectSignarure _______________________________________ __ 
Witness Signarure ---------------------
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RAW DATA 
(in mgfdL) 
SUBJECT NO. TC VLDL-C LDL-C HDL-C 
01 ALLAIN-TRINDER 225 36 152 37 
CHUGAEV 215 27 158 30 
02 ALLAIN-TRINDER 140 12 76 51 
CHUGAEV 143 8 85 51 
03 ALLAIN-TRINDER 229 32 161 36 
CHUGAEV 236 28 153 55 
04 ALLAIN-TRINDER 215 29 152 33 
CHUGAEV 243 19 175 48 
05 ALLAIN-TRINDER 239 41 167 31 
CHUGAEV 248 10 166 71 
06 ALLAIN-TRINDER 162 19 106 36 
CHUGAEV 154 6 96 52 
07 ALLAIN-TRINDER 218 20 140 57 
CHUGAEV 211 6 132 72 
08 ALLAIN-TRINDER 184 15 136 32 
CHUGAEV 195 25 132 38 
09 ALLAIN-TRINDER 135 18 76 40 
CHUGAEV 137 14 79 44 
10 ALLAIN-TRINDER 191 16 141 34 
CHUGAEV 183 20 112 51 
11 ALLAIN-TRINDER 229 32 161 35 
CHUGAEV 226 11 162 53 
12 ALLAIN-TRINDER 250 39 174 36 
CHUGAEV 275 8 188 79 
13 ALLAIN-TRINDER 184 18 83 82 
CHUGAEV 202 7 131 64 
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SUBJECT NO. TC VLDL-C LDL-C HDL-C 
14 ALLAIN-TRINDER 157 16 97 43 
CHUGAEV 175 8 111 56 
15 ALLAIN-TRINDER 220 16 149 55 
CHUGAEV 244 28 135 81 
16 ALLAIN-TRINDER 154 8 101 44 
CHUGAEV 167 11 104 52 
17 ALLAIN-TRINDER 224 20 162 41 
CHUGAEV 232 26 182 24 
18 ALLAIN-TRINDER 254 35 138 81 
CHUGAEV 268 16 183 69 
19 ALLAIN-TRINDER 253 42 176 34 
CHUGAEV 270 8 186 76 
20 ALLAIN-TRINDER 223 27 160 35 
CHUGAEV 226 21 164 41 
21 ALLAIN-TRINDER 232 29 151 52 
CHUGAEV 239 13 169 58 
22 ALLAIN-TRINDER 266 15 212 38 
CHUGAEV 259 30 193 36 
23 ALLAIN-TRINDER 235 12 151 72 
CHUGAEV 232 20 168 44 
24 ALLAIN-TRINDER 218 36 150 31 
CHUGAEV 227 9 158 59 
25 ALLAIN-TRINDER 159 6 103 49 
CHUGAEV 152 12 105 35 
26 ALLAIN-TRINDER 247 12 183 51 
CHUGAEV 244 32 181 31 
27 ALLAIN-TRINDER 159 12 92 55 
CHUGAEV 165 9 115 41 
28 ALLAIN-TRINDER 166 10 115 40 
CHUGAEV 171 10 122 39 
29 ALLAIN-TRINDER 234 14 166 54 
CHUGAEV 231 16 171 43 
30 ALLAIN-TRINDER 238 24 151 63 
CHUGAEV 247 13 172 62 
67 
SUBJECT NO. TC VLDL-C LDL-C HDL-C 
31 ALLAIN-TRINDER 244 22 170 52 
CHUGAEV 256 24 199 34 
32 ALLAIN-TRINDER 160 14 111 35 
CHUGAEV 163 9 108 46 
33 ALLAIN-TRINDER 181 12 103 66 
CHUGAEV 184 12 128 45 
34 ALLAIN-TRINDER 169 11 98 60 
CHUGAEV 177 14 122 41 
35 ALLAIN-TRINDER 171 8 123 39 
CHUGAEV 170 16 115 39 
36 ALLAIN-TRINDER 230 41 150 39 
CHUGAEV 244 14 166 64 
37 ALLAIN-TRINDER 260 17 196 46 
CHUGAEV 260 23 190 46 
38 ALLAIN-TRINDER 243 41 148 53 
CHUGAEV 249 2 167 79 
39 ALLAIN-TRINDER 164 18 96 49 
CHUGAEV 165 9 112 45 
40 ALLAIN-TRINDER 178 13 118 47 
CHUGAEV 181 13 127 41 
41 ALLAIN-TRINDER 204 9 125 69 
CHUGAEV 202 14 146 42 
42 ALLAIN-TRINDER 187 12 116 59 
CHUGAEV 194 16 142 37 
43 ALLAIN-TRINDER 215 23 148 44 
CHUGAEV 226 25 130 72 
44 ALLAIN-TRINDER 253 18 179 55 
CHUGAEV 252 30 190 31 
45 ALLAIN-TRINDER 256 22 192 41 
CHUGAEV 238 32 164 41 
46 ALLAIN-TRINDER 193 17 122 53 
CHUGAEV 200 14 129 57 
47 ALLAIN-TRINDER 165 9 93 62 
CHUGAEV 168 12 119 36 
68 
SUBJECT NO. TC VLDL-C LDL-C HDL-C 
48 ALLAIN-TRINDER 185 21 113 50 
CHUGAEV 177 10 112 56 
49 ALLAIN-TRINDER 214 13 138 62 
CHUGAEV 223 24 161 38 
50 ALLAIN-TRINDER 229 28 159 41 
CHUGAEV 237 20 180 37 
51 ALLAIN-TRINDER 180 43 115 21 
CHUGAEV 159 14 95 50 
52 ALI.AIN-TRINDER 215 38 146 30 
CHUGAEV 197 21 131 45 
53 ALLAIN-TRINDER 228 19 170 39 
CHUGAEV 197 32 133 32 
54 ALLAIN-TRINDER 198 51 104 42 
CHUGAEV 186 13 119 54 
55 ALLAIN-TRINDER 249 21 144 83 
CHUGAEV 233 32 177 24 
56 ALLAIN-TRINDER 183 19 122 41 
CHUGAEV 158 16 98 43 
57 ALLAIN-TRINDER 214 43 144 27 
CHUGAEV 207 18 138 51 
58 ALLAIN-TRINDER 169 20 111 37 
CHUGAEV 165 19 117 29 
59 ALLAIN-TRINDER 189 29 92 67 
CHUGAEV 179 8 116 56 
60 ALLAIN-TRINDER 247 44 168 34 
CHUGAEV 238 28 177 34 
61 ALLAIN-TRINDER 181 18 118 44 
CHUGAEV 175 16 121 38 
62 ALLAIN-TRINDER 253 36 168 48 
CHUGAEV 249 33 187 30 
63 ALLAIN-TRINDER 146 16 98 32 
CHUGAEV 132 12 83 36 
64 ALLAIN-TRINDER 164 14 112 37 
CHUGAEV 156 19 99 38 
69 
SUBJECT NO. TC VLDL-C LDL-C HDL-C 
65 ALLAIN-TRINDER 177 25 112 39 
CHUGAEV 161 15 100 46 
66 ALLAIN-TRINDER 236 29 173 33 
CHUGAEV 215 28 159 28 
67 ALLAIN-TRINDER 152 10 94 48 
CHUGAEV 133 13 69 51 
68 ALLAIN-TRINDER 180 16 111 53 
CHUGAEV 160 23 111 26 
69 ALLAIN-TRINDER 152 15 96 40 
CHUGAEV 118 10 66 42 
70 ALLAIN-TRINDER 133 16 65 52 
CHUGAEV 134 20 88 26 
71 ALLAIN-TRINDER 184 11 130 42 
CHUGAEV 172 19 115 38 
72 ALLAIN-TRINDER 186 21 128 36 
CHUGAEV 177 21 121 35 
73 ALLAIN-TRINDER 179 10 108 61 
CHUGAEV 164 25 126 14 
74 ALLAIN-TRINDER 124 16 62 45 
CHUGAEV 100 8 50 42 
75 ALLAIN-TRINDER 181 29 116 35 
CHUGAEV 142 4 81 58 
76 ALLAIN-TRINDER 220 24 153 42 
CHUGAEV 198 25 132 41 
77 ALLAIN-TRINDER 179 25 116 37 
CHUGAEV 175 18 123 34 
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